ABSTRACT. We have previously described reduced expression of the Fcy receptor type I11 on the cell membrane (M-FcRIII) of neutrophils from very preterm neonates. To investigate the mechanism underlying this reduced receptor expression, we have measured neutrophilderived soluble FcRIII (S-FcRIII) in the plasma of fetuses and neonates from 19 wk gestation. S-FcRIII in fetal plasma and in preterm neonates born before 32 wk gestation was consistently low [mean 13.6 2 1.2% (mean adult S-FcRIII = 100%, range 30-240%)]. I n utero, S-FcRIII starts to rise from 33 wk and increases more than 4-fold to reach adult levels by term. S-FcRIII measured sequentially in preterm infants born as early as 24 wk of gestation showed a rapid postnatal increase to reach adult levels within 3 wk of birth. The changes in S-FcRIII paralleled changes in M-FcRIII expression on the cell surface. These observations point to a reduced rate of FcRIII production by fetal neutrophils as opposed to an increase in receptor release. The parallel increase in S-FcRIII and M-FcRIII suggests that there may be a programmed activation of FcRIII synthesis within individual cells late in the 3rd trimester of fetal development. In addition, FcRIII production may be switched on early by preterm birth. (Pediatr Res 32: 505-508,1992) Abbreviations FcRIII, Fcy receptor type I11 M-FcRIII, neutrophil membrane-associated Fcy receptor type 111 S-FcRIII, soluble plasma Fcy receptor type I11 RDS, respiratory distress syndrome of prematurity CI, confidence interval Little is known about the processes underlying functional maturation of neutrophil immunity during ontogeny. In fullterm neonates, most components of the immune system are still immature: Ig production is limited in quantity and is class restricted (1, 2), and neutrophils are defective in their ability to migrate and kill microorganisms (3). There are few studies of neutrophil functional ability in very immature preterm neonates born before 30 wk of gestation. Those published have demonstrated impaired phagocytosis (4), defective killing (5), and re-
S-FcRIII = 100%, range 30-240%)]. I n utero, S-FcRIII starts to rise from 33 wk and increases more than 4-fold to reach adult levels by term. S-FcRIII measured sequentially in preterm infants born as early as 24 wk of gestation showed a rapid postnatal increase to reach adult levels within 3 wk of birth. The changes in S-FcRIII paralleled changes in M-FcRIII expression on the cell surface. These observations point to a reduced rate of FcRIII production by fetal neutrophils as opposed to an increase in receptor release. The parallel increase in S-FcRIII and M-FcRIII suggests that there may be a programmed activation of FcRIII synthesis within individual cells late in the 3rd trimester of fetal development. In addition, FcRIII production may be switched on early by preterm birth. ( Little is known about the processes underlying functional maturation of neutrophil immunity during ontogeny. In fullterm neonates, most components of the immune system are still immature: Ig production is limited in quantity and is class restricted (1, 2), and neutrophils are defective in their ability to migrate and kill microorganisms (3) . There are few studies of neutrophil functional ability in very immature preterm neonates born before 30 wk of gestation. Those published have demonstrated impaired phagocytosis (4), defective killing (5), and re-duced peak chemiluminescence responses (6, 7) compared with well, full-term neonates and adult controls. There have been no studies comparing the postnatal changes that occur in infants born prematurely at less than 30 wk of gestation with the normal neutrophil functional development that occurs in utero during the last trimester of pregnancy. Consequently, there is little known about the control of normal neutrophil ontogeny and the changes brought about by preterm birth.
We have recently found that the neutrophils from preterm neonates born before 32 wk express reduced numbers of FcRIII, in contrast to normal FcRIII expression by neutrophils from term neonates (8) . Neutrophil FcRIII is encoded by the gene FcRIII-1 (9), which is only expressed in neutrophils. It is linked to the neutrophil cell membrane by a phosphatidylinositol anchor and is shed from the plasma membrane after cell activation (10) . A soluble form of FcRIII of neutrophil origin (S-FcRIII) is present in high concentration in the plasma (1 1). Patients lacking the FcRIII-1 gene express no FcRIII on the neutrophil cell membrane (M-FcRIII) and have no S-FcRIII in their plasma but have normal expression of FcRIII on their natural killer cells and macrophages (encoded by the gene FcRIII-2) (12, 13). Neutrophil membrane FcRIII is involved in the binding of IgGopsonized particles and is able to trigger the lytic machinery of the neutrophil(l4, 15).
To investigate the mechanism underlying reduced M-FcRIII expression by neutrophils from preterm neonates and to chart how this aspect of neutrophil immunity evolves during fetal development, we measured S-FcRIII in neonates and fetuses between 19 wk of gestation and term. In addition, we examined the influence of premature birth by monitoring S-FcRIII and MFcRIII during the early postnatal development of infants born between 24 and 30 wk of gestation.
MATERIALS AND METHODS
Study population. Neutrophils and plasma were collected from 3 1 preterm neonates soon after birth and at intervals during the first weeks of life. The median gestational age was 29 wk (range 23-36 wk). Initial samples were collected within 36 h of birth from infants who had not been transfused with red cells, platelets, or fresh frozen plasma; follow-up samples were collected more than 48 h after any transfusion. Neonates were defined as "well" if they had no evidence of infection and did not require mechanical ventilation for pulmonary insuficiency. Neonates with RDS had typical x-ray changes of hyaline membrane disease and required intensive ventilatory support. Neutrophils and plasma were collected from 15 healthy term neonates at the time of birth by elective cesarean section ( n = 12) or spontaneous vaginal delivery (n = 3). All deliveries by cesarean section were performed under epidural anesthesia before the onset of labor. Fetal plasma samples were collected from 13 unstressed and untransfused fetuses, median gestational age 22 wk (range 19-33 wk), during routine diagnostic percutaneous umbilical cord blood sampling.
The study was approved by and neonatal blood sampling was in accordance with the Liverpool Maternity Hospital Ethical Committee guidelines.
Preparation of samples. (an anti-FcR MAb) was covalently coupled to cyanogen bromideactivated Sepharose 4B beads (10 mg protein to I g Sepharose) and diluted 1:600 in PBS containing EDTA (10 mM) and Tween (0.1 % wt/vol). Five hundred pL of this Sepharose suspension were incubated with 10, 20, and 40 pL of plasma from a test neonate/fetus or with serial doubling dilutions (320 to 1.25 pL) of a plasma pool prepared from 38 normal donors for 18 h at room temperature by head-over-head rotation in 2-mL polystyrene tubes. Each test was performed in triplicate. The Sepharose beads were washed five times with 1.5 mL saline. The anti-FcR MAb BW209/2 was radiolabeled according to the Iodogen method, following the manufacturer's instructions (Pierce, Rockford, IL). Ten pg of labeled MAb were diluted with 500 mL PBS containing EDTA (10 mM), Tween-20 (0.1 % wt/vol) and 1 % normal goat serum to prevent nonspecific binding. Five hundred pL of the labeled MAb solution were added to the tubes and incubated for 5 h with rotation. The tubes were washed five times and radiation measured in a multi-gamma counter (LKB Instruments Inc., Gaithersburg, MD). The amount of S-FcRIII was determined by comparison with the standard calibration curve, generated using the serial dilutions of the pooled plasma as described (1 I). The range of S-FcRIII in the plasma of 25 randomly chosen patients admitted to a general hospital was 40-180%. The range of S-FcRIII in the plasma of the 38 healthy volunteer donors was 30-240%. Assuming that one BW209/2 MAb binds to one FcRIII molecule, 100% would represent a plasma concentration of 5 nM.
Statistical analysis. Study groups are described by mean and SEM. Differences between groups are described by 95% CI, and statistical significance was determined using two-tailed t test. M-FcRIII and gestational age (Fig. 2) . We have previously reported that M-FcRIII expression is reduced in neonates born at <32 wk of gestation compared with term neonates and adults (8) . When M-FcRIII and S-FcRIII were measured simultaneously in neonates in the present study, gestational age-related changes in M-FcRIII expression on the neutrophil cell membrane paralleled S-FcRIII in the plasma. There was no significant change in M-FcRIII between 24 and 32 wk. However, between 33 and 36 wk in utero, M-FcRIII expression increased to reach adult levels by term.
RESULTS

S-FcRIII and gestational age (Figs. 1 and 2). Plasma concentrations of S-
There was quite marked variation in M-FcRIII expression between individual infants. We have previously shown, and confirmed in the present study, that expression of M-FcRIII is transiently down-modulated by sepsis. S-FcRIII appears not to be acutely altered by clinical stress and therefore may be a better index of overall neutrophil maturity. (Fig. 3) . Preterm The postnatal rate of increase in S-FcRIII was not determined by gestational age or clinical status. In contrast, M-FcRIII expression did tend to remain depressed in a few infants with recurrent infections or persistent lung disease. DISCUSSION We have previously described reduced expression of M-FcRIII on the neutrophils of preterm neonates (8) . It was unclear from that observation whether diminished M-FcRIII represented reduced receptor production or increased release from the cell surface as a consequence of in vivo cell activation.
Postnatal changes in S-FcRIII and M-FcRIII
In the present study, we found that the plasma concentration of S-FcRIII is at a consistently low level between 19 and 32 wk of gestation. During a normal pregnancy, S-FcRIII increases abruptly from 33 wk to reach normal adult levels by term. In infants born prematurely, even as early as 24 wk of gestation, there is a rapid postnatal increase in S-FcRIII to reach adult levels within 3 wk of birth. The observed changes in S-FcRIII parallel changes in M-FcRIII expression on the cell surface.
The new observation that low levels of M-FcRIII on the cell surface are associated with very low levels of S-FcRIII in the plasma would favor a reduced rate of receptor production within individual cells as the underlying mechanism. Active synthesis of FcRIII is known to occur in normal mature neutrophils (16, 17) , and continuing protein synthesis is required to maintain normal FcRIII numbers on the cell membrane (1 8). In congenital FcRIII-1 deficiency and in paroxysmal nocturnal hemoglobinuria, conditions in which functional FcRIII synthesis is absent or defective, there are absent or low levels of FcRIII both on the neutrophil cell membrane and in the plasma (10, 13, 19) . The alternative explanation, increased receptor shedding, would seem less likely to result in the low plasma levels of S-FcRIII observed if the underlying rate of receptor synthesis was normal.
We speculate that the parallel increase in S-FcRIII and MFcRIII, which occurs between 33 and 36 wk of gestation, may indicate a programmed activation of receptor synthesis within individual cells. An external trigger for this maturation step may be provided by the cytokines granulocyte colony stimulating factor or granulocyte/macrophage colony stimulating factor. Both increase the expression of FcRIII on neutrophils in vitro by a mechanism that appears to require new receptor synthesis (20) . Moreover, high concentrations of both granulocyte colony stimulating factor and granulocyte/macrophage colony stimulating factor have been reported in cord blood from term infants (2 1).
Further investigation of this phenomenon, by direct measurement of neutrophil FcRIII receptor synthesis and mRNA transcription during fetal development, may reveal control mechanisms amenable to therapeutic intervention for the future enhancement of neonate neutrophil function. sor C. H. Rodeck at the Institute of Obstetrics and Gynaecology, Royal Postgraduate Medical School, London, for providing fetal plasma samples. Thanks also go to Diane Pumford for technical assistance.
